Physician profile
Christopher Aderman
NPI 1912260381
$211,430.07
in general payments reported to CMS, 2019-2025
16 companies · $34K in 2025
The $34K reported for 2025 was more than what 96% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,233 · 2020: $29K · 2021: $9,574 · 2022: $16K · 2023: $42K · 2024: $72K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $105K · Consulting Fee: $24K · Travel and Lodging: $14K · Food and Beverage: $5,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $105,413.30 |
| Consulting Fee | $23,910.50 |
| Travel and Lodging | $13,864.36 |
| Food and Beverage | $5,355.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $130,757.11 | 2019-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $47,194.53 | 2023-2025 | Izervay |
| Genentech USA, INC. | $15,207.29 | 2019-2025 | Vabysmo |
| Regeneron Pharmaceuticals, INC. | $10,214.52 | 2021-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $3,376.95 | 2022-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $3,287.03 | 2019-2021 | |
| Genentech, INC. | $732.59 | 2021-2024 | Vabysmo, Susvimo, Lucentis |
| Alimera Sciences, INC. | $239.44 | 2024 | Iluvien, Yutiq |
| Abbvie INC. | $130.89 | 2023 | Ozurdex |
| Astellas Pharma Global Development | $91.23 | 2025 | Izervay |
| Dutch Ophthalmic, USA | $79.66 | 2019 | |
| Harrow Eye, LLC | $64.56 | 2024-2025 | Iheezo, Flarex, Tobradex St |
| Alcon Vision LLC | $31.50 | 2024 | Argos |
| Ocular Therapeutix, INC. | $22.77 | 2025 | Dextenza |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Aderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.